{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:18:38Z","timestamp":1793449118000,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":56,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alz &amp;amp; Dem Diag Ass &amp;amp; Dis Mo"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Real\u2010world safety data on amyloid\u2010targeted therapies in early Alzheimer's disease remain limited, particularly for modified donanemab titration and direct lecanemab\u2013donanemab comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Retrospective review of 172 amyloid\u2010positive patients treated with lecanemab (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a089) or donanemab (original titration\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a021; modified\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a062). The cohort included patients with \u22652 chronic comorbidities (72.7%), systemic autoimmune or hematologic disorders, and concurrent immunomodulators.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Amyloid\u2010related imaging abnormalities (ARIA) occurred in 11.2% (10\/89) with lecanemab and 13.3% (11\/83) with donanemab\u2014less than in pivotal trials. Modified donanemab titration reduced ARIA versus the original protocol (8.1%\u00a0vs 28.6%;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.03) and TRAILBLAZER\u2010ALZ 6 (23.6%). No anaphylaxis occurred. Surveillance magnetic resonance imaging captured 95.2% of ARIA events. Within\u2010center comparison showed comparable safety between lecanemab and modified\u2010titration donanemab (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2019s\u00a0&gt;\u00a00.40). IRRs occurred in 12.0% (donanemab) and 9.0% (lecanemab).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>In a real\u2010world cohort representing patients excluded from trials, ARIA and IRR rates matched or improved upon pivotal trials, supporting safe ATT use under FDA\u2010approved MRI intervals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/dad2.70404","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:17:32Z","timestamp":1787800652000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2010world evidence for amyloid\u2010targeted therapies: Lecanemab and donanemab"],"prefix":"10.1002","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-9113","authenticated-orcid":false,"given":"Ryan","family":"Hakim","sequence":"first","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristofer","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Merrill","sequence":"additional","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Falk\u2010Vargas","sequence":"additional","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Whalen","sequence":"additional","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxu","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ochoa","sequence":"additional","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hunter","sequence":"additional","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Ernest","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Neurology The McGovern Medical School of UTHealth  Houston Texas USA"},{"name":"UTHealth Graduate School of Biomedical Sciences  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4405"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010025\u201002961\u20106"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371405901202"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.24005"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cdt3.155"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gerinurse.2025.05.010"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0065"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52042"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230009"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12377"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205071"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.22.28461"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8469"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7586"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.065856"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102981"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1326784"},{"key":"e_1_2_13_25_1","article-title":"beta\u2010amyloid PET signal reduction in prior ARIA\u2010E regions after anti\u2010amyloid therapy for Alzheimer's disease","author":"Finn Q","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70062"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010025\u201000756\u20104"},{"key":"e_1_2_13_28_1","article-title":"Initial real\u2010world evidence for Lecanemab in the United States","author":"Brixner DI","year":"2025","journal-title":"Drugs Aging"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010025\u201001763\u20101"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211951"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1559447"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japhar.2025.100015"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_13_35_1","article-title":"A practical approach to selecting patients for amyloid\u2010targeting treatments","author":"Abi Chakra N","year":"2025","journal-title":"Practical Neurology"}],"container-title":["Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dad2.70404","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:56:48Z","timestamp":1791392208000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/dad2.70404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/dad2.70404"],"URL":"https:\/\/doi.org\/10.1002\/dad2.70404","archive":["Portico"],"relation":{},"ISSN":["2352-8729","2352-8729"],"issn-type":[{"value":"2352-8729","type":"print"},{"value":"2352-8729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70404"}}